Nemes Rush Group’s AbbVie ABBV Stock Holding History

Nemes Rush Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.48M	Buy	16,011 +153	+1%	+$33.9K	0.33%	63
2025 Q4	$3.62M	Buy	15,858 +157	+1%	+$35.8K	0.34%	61
2025 Q3	$3.64M	Buy	15,701 +921	+6%	+$188K	0.36%	55
2025 Q2	$2.74M	Buy	14,780 +11,440	+343%	+$2.13M	0.3%	62
2025 Q1	$700K	Sell	3,340 -378	-10%	-$73.5K	0.09%	107
2024 Q4	$661K	Sell	3,718 -417	-10%	-$76.7K	0.08%	108
2024 Q3	$753K	Buy	4,135 +244	+6%	+$45.5K	0.11%	100
2024 Q2	$667K	Sell	3,891 -295	-7%	-$48.9K	0.09%	105
2024 Q1	$762K	Sell	4,186 -96	-2%	-$16.5K	0.11%	100
2023 Q4	$664K	Sell	4,282 -747	-15%	-$109K	0.11%	113
2023 Q3	$750K	Sell	5,029 -1,663	-25%	-$244K	0.14%	101
2023 Q2	$902K	Buy	+6,692	New	+$981K	0.16%	90

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nemes Rush Group's ABBV Position: Q1 2026 in Review

Nemes Rush Group increased its AbbVie (ABBV) stake by 0.96% in Q1 2026, buying an estimated $33.9K and bringing the position to 16,011 shares worth $3.48M. The position accounts for 0.33% of the portfolio, ranked #63.

Nemes Rush Group first reported a position in ABBV in Q2 2023 and has held it in 12 quarters since. The position peaked at $3.64M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Nemes Rush Group held 16,011 shares of AbbVie worth $3.48M as of Q1 2026.
Nemes Rush Group bought 153 AbbVie shares in Q1 2026, an estimated $33.9K.
AbbVie made up 0.33% of Nemes Rush Group's portfolio in Q1 2026, its #63 holding.
Nemes Rush Group first reported a position in AbbVie in Q2 2023 and has held it in 12 quarters since.
Nemes Rush Group's AbbVie position peaked at $3.64M in Q3 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.